Weekly roundup: Another great year at Anglonordic
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works.
The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks.
Keep reading to hear more about what’s been happening this week.
Xeltis received CE mark for aXess™, its hemodialysis conduit, and releases groundbreaking new 12-month EU pivotal data as it moves to commercialization
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announced it received CE mark for aXess™, its restorative vascular access conduit for hemodialysis treatment, marking the Company’s transition to a commercial‑stage organization. Xeltis also announced new 12‑month clinical data from the aXess multi-center EU pivotal trial, which enrolled 120 patients in 22 clinical trial sites from nine European countries, demonstrating the transformative potential of aXess™ in hemodialysis treatment.
Asgard Therapeutics presented preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, announced that it presented a poster on its lead asset AT-108 at the AACR Annual Meeting, held in San Diego, California, US, from 17-22 April 2026.
Oncoinvent announced the publication of its Annual Report for 2025
Oncoinvent ASA, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, announced the publication of the Annual Report for 2025, which is available in the investor section of the Company’s website here.
📺Optimum TV
Investors can’t do the work for you – companies need to come prepared. In this brand-new episode of Optimum TV’s Dealmaker series Hakan Goker, Managing Director of M Ventures, speaks about how companies can cut through the noise and get noticed by making use of networks, getting those conversations started and coming with a clear and compelling story.
To watch the full episode for more tips and learnings, direct from leading life science investors, head to our channel here.
👥Industry events
Anglonordic Life Sciences Conference XXII – London | 23rd Apr 2026
The Anglonordic Life Science Conference 2026 was a great success, building on 22 years of history and experience. Check out the LinkedIn page to see who you can spot.
Bio€quity Europe Conference – Prague | 4-6th May 2026
In just over a week’s time, Bio€quity Europe will take centre stage in Prague, bringing together global leaders, investors and innovators to network, forge partnerships and debate the critical issues facing the biotech industry. With insightful panel discussions, company presentations and one‑to‑one partnering meetings, the event focuses on emerging science, investment trends and the forces shaping the future of biotech.
Mary Clark, CEO, and Zoe Bolt, Associate Director, will be attending and look forward to catching up with colleagues and making new connections. To schedule a meeting, please reach out via LinkedIn or at healthcare@optimumcomms.com.
LSX Nordic Congress – Copenhagen | 19-20th May 2026
🤝 Why Attend?
From formal partnering sessions to spontaneous coffee station conversations, this is where authentic, face-to-face connections happen. Whether you’re an innovator, investor, or strategic partner, the LSX Nordic Congress is your gateway to meaningful collaborations.
The partnering portal opens on Tuesday 21st April.
Reach out to use Optimum’s exclusive F&F discount!
On Helix – Cambridge | 9th Jul 2026
Just three months until One Nucleus presents ON Helix – Disrupting Bio Innovation.
A one-day conference in Cambridge spotlighting and discussing breakthrough technologies, policies and business models that are shaping the drug discovery and development landscape.
An excellent opportunity to connect with the pioneers leading this next wave of disruptive innovation and ensure you stay ahead in a rapidly evolving space.
Optimum is a proud supporter of One Nucleus events and is happy to share an exclusive 10% F&F discount. Please get in touch if you would like to optimise this or connect with the team there!
Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026
Save the date – Thursday the 8th of October 2026!
The date is set for Optimum’s 18th Annual Healthcare Investor Conference, which returns to the King’s Fund, London this October.
Join us for a day of invaluable insights from the thought leaders of the life sciences industry! The conference is free but invitation only, so please register your interest to attend here: https://www.optimumcomms.com/irconference2026/
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
